Table 4.
Adjusted Means and the 95% Confidence Intervals of Efficacy and Tolerability Outcomes by Combined Phenotype Groups
| |
Means (95% CI)aCombined metabolizing subgroup (n = 279) |
||||
|---|---|---|---|---|---|
| C-PM (n = 55) | C-IM (n = 62) | C-EM (n = 145) | C-UM (n = 17) | p Value for trend | |
| Efficacy outcomes | |||||
| Behavioral Intervention Score | 0.20 (0.04–0.39) | 0.31 (0.18–0.46) | 0.44 (0.30–0.59) | 0.57 (0.37–0.80) | 0.01 |
| Number of PRN doses | 1.07 (0.61–1.67) | 1.27 (0.89–1.72) | 1.48 (1.08–1.97) | 1.72 (1.14–2.47) | 0.14 |
| Length of stay | 6.36 (5.43–7.45) | 6.58 (5.87–7.38) | 6.81 (6.09–7.61) | 7.04 (6.05–8.19) | 0.38 |
| Change of GAF | 22.7 (21.0–24.4) | 22.7 (21.5–23.9) | 22.6 (21.5–23.8) | 22.6 (21.0–24.2) | 0.90 |
| Tolerability outcome | |||||
| Number of ADRs | 1.44 (0.96–2.00) | 1.19 (0.88–1.54) | 0.96 (0.69–1.26) | 0.75 (0.43–1.13) | 0.03 |
a
Data presented as adjusted means and 95% confidence interval (CI) with adjusters set at the mean or reference category (sex = female, Age = 13, admit GAF = 20, number of psychiatric drugs = 2, psychotic disorder = no, anxiety disorder = no, impulse control disorder = no, pervasive developmental disorder = no).
Abbreviations: C-PM = combined poor metabolizing phenotype; C-IM = combined intermediate metabolizing phenotype; C-EM =combined extensive metabolizing phenotype; C-UM = combined ultrarapid metabolizing phenotype; PRN = as needed; GAF = Global Assessment of Functioning score; ADRs = adverse drug reactions.